OGN ▼ -0.1% - Organon & Co. $OGN Organon Presents New Analysis of Pooled Post-Hoc Phase 3 Data on VTAMA® (tapinarof) cream, 1%, Demonstrating Consistent Efficacy in Atopic Dermatitis Across Diverse Patient Subgroups at ACAAI 12-NOV-2026 10:00 AM ET